Update on Targeted Therapy in Medullary Thyroid Cancer
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor that accounts for 2-4% of all thyroid cancers. All inherited MTC and approximately 50% of sporadic cases are driven by mutations in the REarranged during Transfection (RET) proto-oncogene. The recent expansion of the armamentarium of R...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-08-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.708949/full |
| _version_ | 1819137511825342464 |
|---|---|
| author | Christian Okafor Julie Hogan Margarita Raygada Barbara J. Thomas Srivandana Akshintala John W. Glod Jaydira Del Rivero |
| author_facet | Christian Okafor Julie Hogan Margarita Raygada Barbara J. Thomas Srivandana Akshintala John W. Glod Jaydira Del Rivero |
| author_sort | Christian Okafor |
| collection | DOAJ |
| description | Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor that accounts for 2-4% of all thyroid cancers. All inherited MTC and approximately 50% of sporadic cases are driven by mutations in the REarranged during Transfection (RET) proto-oncogene. The recent expansion of the armamentarium of RET-targeting tyrosine kinase inhibitors (TKIs) has provided effective options for systemic therapy for patients with metastatic and progressive disease. However, patients that develop resistant disease as well as those with other molecular drivers such as RAS have limited options. An improved understanding of mechanisms of resistance to TKIs as well as identification of novel therapeutic targets is needed to improve outcomes for patients with MTC. |
| first_indexed | 2024-12-22T10:52:03Z |
| format | Article |
| id | doaj.art-4fa88b3f6e264294930a622dd17b53fc |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-22T10:52:03Z |
| publishDate | 2021-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-4fa88b3f6e264294930a622dd17b53fc2022-12-21T18:28:44ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922021-08-011210.3389/fendo.2021.708949708949Update on Targeted Therapy in Medullary Thyroid CancerChristian Okafor0Julie Hogan1Margarita Raygada2Barbara J. Thomas3Srivandana Akshintala4John W. Glod5Jaydira Del Rivero6Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United StatesPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United StatesPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United StatesPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United StatesPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United StatesPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United StatesDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United StatesMedullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor that accounts for 2-4% of all thyroid cancers. All inherited MTC and approximately 50% of sporadic cases are driven by mutations in the REarranged during Transfection (RET) proto-oncogene. The recent expansion of the armamentarium of RET-targeting tyrosine kinase inhibitors (TKIs) has provided effective options for systemic therapy for patients with metastatic and progressive disease. However, patients that develop resistant disease as well as those with other molecular drivers such as RAS have limited options. An improved understanding of mechanisms of resistance to TKIs as well as identification of novel therapeutic targets is needed to improve outcomes for patients with MTC.https://www.frontiersin.org/articles/10.3389/fendo.2021.708949/fullmedullary thyroid cancer (MTC)MEN2calcitonintyrosine kinase inhibitorclinical trials |
| spellingShingle | Christian Okafor Julie Hogan Margarita Raygada Barbara J. Thomas Srivandana Akshintala John W. Glod Jaydira Del Rivero Update on Targeted Therapy in Medullary Thyroid Cancer Frontiers in Endocrinology medullary thyroid cancer (MTC) MEN2 calcitonin tyrosine kinase inhibitor clinical trials |
| title | Update on Targeted Therapy in Medullary Thyroid Cancer |
| title_full | Update on Targeted Therapy in Medullary Thyroid Cancer |
| title_fullStr | Update on Targeted Therapy in Medullary Thyroid Cancer |
| title_full_unstemmed | Update on Targeted Therapy in Medullary Thyroid Cancer |
| title_short | Update on Targeted Therapy in Medullary Thyroid Cancer |
| title_sort | update on targeted therapy in medullary thyroid cancer |
| topic | medullary thyroid cancer (MTC) MEN2 calcitonin tyrosine kinase inhibitor clinical trials |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2021.708949/full |
| work_keys_str_mv | AT christianokafor updateontargetedtherapyinmedullarythyroidcancer AT juliehogan updateontargetedtherapyinmedullarythyroidcancer AT margaritaraygada updateontargetedtherapyinmedullarythyroidcancer AT barbarajthomas updateontargetedtherapyinmedullarythyroidcancer AT srivandanaakshintala updateontargetedtherapyinmedullarythyroidcancer AT johnwglod updateontargetedtherapyinmedullarythyroidcancer AT jaydiradelrivero updateontargetedtherapyinmedullarythyroidcancer |